Iterum Therapeutics Soars 11.43% on H.C. Wainwright Buy Rating

On May 9, 2025, Iterum Therapeutics saw a significant rise of 11.43% in pre-market trading, indicating a strong start to the day's session.

Iterum Therapeutics has recently received a Buy rating from H.C. Wainwright, with a price target set at $9. This rating comes as part of the firm's initiation of coverage on the stock, reflecting a positive outlook on the company's prospects.

The Buy rating from H.C. Wainwright is based on the firm's analysis of Iterum Therapeutics' current position and future potential. The price target of $9 suggests that the firm expects the stock to appreciate significantly from its current levels, driven by the company's strategic initiatives and market opportunities.